FDA Rejects Preterm Birth Drug From Watson, Columbia
The U.S. Food and Drug Administration rejected an application from Watson Pharmaceuticals Inc. and Columbia Laboratories Inc. on Monday for a progesterone drug intended to reduce the risk of preterm birth,...To view the full article, register now.
Already a subscriber? Click here to view full article